Type 1, liver kidney microsomal autoantibodies (LKM-1) are associated with a subgroup of idiopathic autoimmune type, chronic active hepatitis (CAH). The antigenic specificity of LKM-1 autoantibodies from 13 patients was investigated by immunoblot analysis of human liver microsomal proteins. Polypeptides of 50, 55, and 64 kD were detected with these antisera. A high titer LKM-1 serum was selected to screen a human liver lambda gt11 cDNA expression library, resulting in the isolation of several complementary (c)DNA clones. Autoantibodies affinity purified from proteins expressed by two of the immunopositive cDNA clones, HLD8.2 and HLD13.2, specifically react with a 50-kD protein of human liver microsomes and display immunofluorescence staining of the proximal renal tubular epithelia characteristic of LKM-1 sera. Determination of the sequence of HLD8.2 revealed that it encodes a recently described cytochrome P450db1. A bacterial fusion protein constructed from HLD8.2 proved to be a specific and sensitive diagnostic reagent. All sera from patients with LKM-1 positive liver disease react with this fusion protein. No reaction was seen, however, for sera from patients with other types of autoimmune liver diseases, viral hepatitis, systemic immunological disorders, or healthy controls.
Introduction
This study was directed toward the identification of the proteins recognized by type 1 liver kidney microsomal antibodies (LKM-1)' autoantibodies associated with some forms of chronic active hepatitis (CAH). CAH is a clinically and morphologically defined syndrome arising from a variety of differ-A preliminary report on this work was presented at the Annual Meeting of the American Gastroenterological Association, 14-18 May 1988, New Orleans, LA. ent etiologies (1, 2) . In addition to hepatitis B virus (HBV) induced CAH, HBV negative CAH consists of a diverse group of diseases, including non-A, non-B viral CAH, and idiopathic autoimmune type CAH. Autoimmune CAH is often associated with a predominance of female over male patients (8:1) , with hypergammaglobulinemia and nonhepatic autoimmune syndromes, as well as with HLA phenotypes B8 and DR3 (1) . Analysis of circulating autoantibodies has defined three subgroups of idiopathic autoimmune type CAH (1-3). LKM-1 autoantibodies characterize one subgroup of idiopathic autoimmune CAH (1) (2) (3) (4) (5) (6) (7) . LKM-l antibodies are not associated with either classical autoimmune CAH, which is positive for antinuclear antibody (1, 7, 8) or with the third subgroup, characterized by autoantibodies against a soluble liver antigen (SLA) (1) . LKM autoantibodies were originally described by immunofluorescence exhibiting a typical cytoplasmic staining of hepatocytes and proximal renal tubular epithelia (9) . Sera from such patients react on Western blots with a 50-kD microsomal protein (1O, 1 1) . LKM-1 antibodies are distinguished from LKM-2 antibodies, which have a similar immunofluorescence pattern, but which are specifically associated with drug-induced hepatitis caused by tienilic acid (ticrynafen) (1 1) .
In the present study, we describe the heterologous pattern of LKM-1 autoantibody specificities assayed by immunoblot analysis of human liver microsomal proteins. In order to identify and characterize the antigen(s) recognized by LKM-1 autoantibodies, a high titer LKM-1 positive serum was used as a probe to screen a Xgtl 1 cDNA expression library. We report here the isolation of a human liver cDNA that corresponds to the 50-kD antigen recognized by LKM-1 autoantibodies. Sequence analysis of this cDNA reveals that it encodes cytochrome P450dbl, the cytochrome P450 responsible for widespread polymorphism in the ability to metabolize certain antihypertensive drugs including debrisoquine (12). A bacterial fusion polypeptide produced in plasmid pATH 11 proved to be a specific and sensitive diagnostic tool for the detection of LKM-1 autoantibodies in patient sera.
Methods
Patient sera. 13 LKM-1 positive sera from patients with hepatitis B surface antigen (HBsAg) negative chronic hepatitis were the focus of this study. Three sera that exhibited a characteristic LKM type immunofluorescence pattern but from patients with no evidence of liver disease were also examined. These three sera from patients with idiopathic thrombocytopenia, scleroderma, and chronic sinusitis, respectively, were selected on the basis of their LKM immunofluorescence from several hundred autoimmune sera collected at Scripps Clinic and Research Foundation. They are tabulated together with the 13 CAH sera in Table I to emphasize their distinct antibody specificity. In addition, sera from 103 patients with various liver diseases, from 34 patients with systemic immunological disorders, from 20 patients with various malignancies, and from 20 healthy blood donors were included in this study. The group of 103 patients with liver diseases consisted ofpatients with classical autoimmune type "lupoid" CAH (n = 10) positive for antinuclear antibodies, patients with SLA antibody positive autoimmune type CAH (n = 10), hepatitis B virus-induced CAH (n = 10), CAH non-A-non-B (n = 10), CAH due to hepatitis D (delta) virus infection (n = 10), acute viral hepatitis A (n = 5), B (n = 10), non-A-non-B (n = 6), antimitochondrial antibody (AMA) positive primary biliary cirrhosis (PBC) (n = 20), and extrahepatic cholestasis due to bile duct calculi (n = 20). The 34 patients with systemic immunological disorders consisted ofpatients with systemic lupus erythematosus (n = 11), scleroderma (n = 5), rheumatoid arthritis (n = 4), Wegener's granulomatosis (n = 1), Reiter's disease (n = 4), Crohn's disease (n = 6), sarcoidosis (n = 3). The group of 20 patients with malignancies consisted of carcinoma of the stomach (n = 3), pancreas (n = 2), colon (n = 5), and rectum (n = 4), malignant melanoma (n = 3), as well as lung (n = 2) and breast cancer (n = 1). All these sera were tested for LKM antibodies by indirect immunofluorescence on rodent liver and kidney sections, Western blots with human liver microsomes and against recombinant LKM-1 antigen as will be described below. These sera were collected at the I. Department of Internal Medicine, University of Mainz, FRG, which is a reference laboratory for liver diseases.
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Immunological methods. Autoantibodies were tested by immunofluorescence on mouse liver and kidney cryostat tissue sections (6, 9) . LKM and SLA antibodies were assayed by radioimmunoassay as described previously (1, 6) . Immunoblotting analysis of patient sera was performed as described previously (13 further analysis. DNA sequence analysis was performed using the dideoxy method (17) . The sequence of the cDNA was determined on both strands from a set of overlapping restriction fragments subcloned into Ml 3 or Bluescript.
Preparation of affinity purified antibodies. Fusion proteins ex- Fusion protein analysis. For immunoblot analysis using the cloned antigen, the cDNA was subcloned into the fusion protein vector, pATH 11 (kindly provided by T. J. Koerner, Duke University, Durham, NC). pATH 11 contains the 5' portion of the E. coli trpE gene, encoding 36 kD of anthranilate synthetase followed by a polylinker that possesses an Eco RI site in the same translational frame as the Eco RI site of Xgtl 1. After ligation and transformation into E. coli RR-1, colonies were selected, cultured, and processed for immunoblot analysis as described previously ( 18) .
Results
Immunoblotting analysis. Sera from 13 hepatitis patients, each positive for LKM-1 antibodies as determined by immunofluorescence were tested for reactivity with human microsomal proteins by immunoblot analysis (Fig. 1 ). These patients were diagnosed as having HBsAg negative chronic active or persistent hepatitis. Among the LKM-1 positive CAH sera, a heterogeneous pattern of reactivity with human microsomal proteins was observed. Seven of the LKM-1 positive hepatitis sera showed reactivity with a 50-kD microsomal protein of human liver microsomes. Sera 5 and 6 showed only very weak reactivity. This is consistent with previous reports (10) of the reactivity of LKM-1 antibodies with a 50-kD protein in human liver microsomes. Four sera reacted with a different microsomal protein of 64 kD ( Fig. 1, sera 9 , 10, 11, 13) and one with an additional protein at 55 kD (Fig. 1, serum 2) .
Three sera from patients with idiopathic thrombocytopenia, scleroderma, or chronic sinusitis, respectively, were also tested because they exhibited immunofluorescence on sections of mouse liver and kidney similar to that of LKM-I autoantibodies (6, 9) . These patients did not exhibit evidence of liver disease, and the three sera did not react with human microsomal proteins as judged by immunoblotting (Fig. 1) . Additional sera from 103 patients with degenerative liver diseases including autoimmune CAH with associated SLA and ANA autoantibodies, viral hepatitis, primary biliary cirrhosis, and extrahepatic cholestasis due to bile duct calculi were negative.
Sera from 34 patients with systemic immunologic disorders, from 20 patients with various malignancies, as well as from 20 healthy blood donors were also negative by immunoblot analysis.
Isolation ofan LKM-I cDNA. A high titer LKM-l autoantibody positive serum was selected to screen a human liver cDNA expression library constructed in Xgtl . This serum (Fig. 1, serum 10) 10 . After extensive washing, bound antibodies were eluted from the filters and used for immunoblot analysis of human microsomal proteins. Antibodies eluted from proteins expressed by each of the LKM-l positive cDNA clones reacted specifically with the 50-kD microsomal protein of human liver microsomes (Fig. 2 a, lanes 2  and 3) . The specificity of the immunoaffinity purification procedure was verified by the lack of reactivity of antibodies recovered from control filters (Fig. 2 a, lane 4) and by the lack of reactivity of the purified antibodies with the 64-kD antigen, recognized by the original serum. Furthermore, using the immunofluorescence assay, autoantibodies affinity purified from proteins expressed by cloned LKM-1 cDNAs reacted with the proximal renal tubules of mouse with a pattern indistinguishable from that of the original serum (Fig. 2 b) . These The reactivities of sera 5 and 6 with the 50-kD antigen were weak and were not reproduced in the photograph.
amino acid sequences (Fig. 3) . Human cytochrome P450 IID is a microsomal protein with an apparent Mr of 50,000 (20), which corresponds in size to the 50-kD antigen identified in human liver microsomes by the affinity purified autoantibody. The use of recombinant antigen for detection of LKM-J autoantibodies in patient sera. Because the clinical distinction between non-A, non-B viral, and autoimmune hepatitis has important implications for disease management, it was of interest to examine the utility ofthe cloned LKM-I antigen as an assay for LKM-1 autoantibodies. The HLD8.2 cDNA was subcloned into pATH 1 (Fig. 4) . The reactivity of all of the antisera toward the bacterial lysates was then examined by immunoblotting. Only sera showing the LKM-1 fluorescence pattern that were derived from patients with liver disease (Fig. 5, lanes 1-13) 
Discussion
The sequence of HLD8.2 demonstrates that it encodes the human class 1ID cytochrome P450, P450dbl (12). Identification ofcytochrome P450db 1 as a major autoantigen in LKM-I positive nonviral CAH rests on three lines of evidence. First, the cDNA encoded antigen is recognized by LKM-l antisera and specifically selects antibodies from patient sera that are reactive against a 50-kD antigen in human liver microsomes. The molecular weight and subcellular localization of cytochrome P450db 1 (20) are consistent with this identification. Secondly, all 13 available LKM-I antibody positive sera from patients with liver disease react with a recombinant fusion protein constructed from the P450db1 cDNA. Neither sera from patients with other forms of autoimmune liver disease, viral hepatitis, nor sera from patients with various systemic immunological disorders, malignancies, or healthy controls react with the recombinant antigen. Thirdly, LKM-l autoantibodies affinity purified on recombinant antigen reacted with the proximal tubular cells of mouse kidney with an immunofluorescent pattern characteristic of LKM-1 antisera. We conclude that autoantibodies directed against epitopes present on cytochrome P450db 1 are a characteristic feature ofthe LKM-1 subgroup of idiopathic autoimmune hepatitis2 (1, 3) . The mechanisms triggering the production of LKM-1 autoantibodies to P450dbl and its relation to the pathogenesis of liver tissue injury remain unknown. LKM-1 autoantibody production could be a secondary phenomenon related to the release of the P450dbl antigen as result of liver damage in individuals genetically able to mount an immune response to it. However, the fact that LKM-l antibodies were not observed 2. While this manuscript was in review, Zanger et al. (24) provided us with a preprint of their manuscript describing the capacity of four LKM-1 antisera from French children to inhibit the catalytic activity of P450dbl. Another report was published (25) describing the reactivity of LKM-I antisera derived from French children toward rat liver cDNAs. It is thought that these cDNAs code for the rat equivalent of P450dbl based on restriction mapping. cates a heterogeneity in the humoral immune response to liver microsomal antigens among these patients. The affinity purified antibody did not, however, react with either the 64-kD microsomal antigen nor with the 55-kD protein recognized by complete serum 2 (Fig. 1) . Therefore the 64-and 55-kD epitopes are not encoded by our cloned cDNA. Whether and how antibodies to these additional proteins are related to autoimmune CAH is unknown and has not been addressed in this study. It would be premature to draw any conclusions at this time regarding the role of these autoantibodies in disease pathogenesis.
The recombinant antigen developed in this study provides a reagent for the identification of LKM-l autoantibodies that are associated with idiopathic autoimmune CAH. The use of the recombinant antigen appears to provide greater sensitivity for the detection of LKM-1 autoantibodies than human liver microsomes as judged by a comparison of Figs. 1 and 5. Autoimmune CAH represents a significant fraction of HBsAg negative chronic hepatitis (1) (2) (3) . Immunosuppressive therapy has been shown to improve life expectancy for patients suffering from autoimmune CAH (23) . Thus, the identification of LKM-1 positive liver disease would help to select patients who might respond to immunosuppressive therapy. LKM-1 positive liver disease is presently recognized to comprise 10% of all HBsAg negative CAH patients and -25% of all autoimmune CAH patients (6) . The frequency of occurrence in the French population was reported as 5:1,000,000 (3). Improved diagnostic procedures facilitated by the use ofthe cloned, recombinant antigen could lead to an upward revision of these estimates. 
